Tissue | Expression Dynamics | Abbreviation |
Esophagus | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Esophagus/CHERP_pca_on_diff_genes.png) | ESCC: Esophageal squamous cell carcinoma |
HGIN: High-grade intraepithelial neoplasias |
LGIN: Low-grade intraepithelial neoplasias |
Liver | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Liver/CHERP_pca_on_diff_genes.png) | HCC: Hepatocellular carcinoma |
NAFLD: Non-alcoholic fatty liver disease |
Oral Cavity | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/OralCavity/CHERP_pca_on_diff_genes.png) | EOLP: Erosive Oral lichen planus |
LP: leukoplakia |
NEOLP: Non-erosive oral lichen planus |
OSCC: Oral squamous cell carcinoma |
Thyroid | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Thyroid/CHERP_pca_on_diff_genes.png) | ATC: Anaplastic thyroid cancer |
HT: Hashimoto's thyroiditis |
PTC: Papillary thyroid cancer |
GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
GO:0051235110 | Esophagus | ESCC | maintenance of location | 200/8552 | 327/18723 | 1.01e-08 | 2.02e-07 | 200 |
GO:0051651111 | Esophagus | ESCC | maintenance of location in cell | 126/8552 | 214/18723 | 6.57e-05 | 5.00e-04 | 126 |
GO:005123521 | Liver | HCC | maintenance of location | 185/7958 | 327/18723 | 1.70e-07 | 3.12e-06 | 185 |
GO:005165112 | Liver | HCC | maintenance of location in cell | 119/7958 | 214/18723 | 7.11e-05 | 6.39e-04 | 119 |
GO:005123518 | Oral cavity | OSCC | maintenance of location | 182/7305 | 327/18723 | 6.16e-10 | 1.58e-08 | 182 |
GO:005165120 | Oral cavity | OSCC | maintenance of location in cell | 121/7305 | 214/18723 | 1.39e-07 | 2.32e-06 | 121 |
GO:00331733 | Oral cavity | OSCC | calcineurin-NFAT signaling cascade | 26/7305 | 43/18723 | 3.55e-03 | 1.49e-02 | 26 |
GO:00480164 | Oral cavity | OSCC | inositol phosphate-mediated signaling | 30/7305 | 55/18723 | 1.39e-02 | 4.59e-02 | 30 |
GO:00708843 | Oral cavity | OSCC | regulation of calcineurin-NFAT signaling cascade | 20/7305 | 34/18723 | 1.51e-02 | 4.91e-02 | 20 |
GO:0050850 | Oral cavity | OSCC | positive regulation of calcium-mediated signaling | 19/7305 | 32/18723 | 1.56e-02 | 5.00e-02 | 19 |
GO:0051235112 | Thyroid | PTC | maintenance of location | 148/5968 | 327/18723 | 2.30e-07 | 4.07e-06 | 148 |
GO:0051651113 | Thyroid | PTC | maintenance of location in cell | 100/5968 | 214/18723 | 3.65e-06 | 4.67e-05 | 100 |
GO:005123532 | Thyroid | ATC | maintenance of location | 152/6293 | 327/18723 | 7.84e-07 | 1.04e-05 | 152 |
GO:005165133 | Thyroid | ATC | maintenance of location in cell | 105/6293 | 214/18723 | 1.92e-06 | 2.31e-05 | 105 |
GO:00508483 | Thyroid | ATC | regulation of calcium-mediated signaling | 36/6293 | 73/18723 | 3.91e-03 | 1.70e-02 | 36 |
Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
CHERP | SNV | Missense_Mutation | rs201274229 | c.2626G>A | p.Val876Ile | p.V876I | Q8IWX8 | protein_coding | tolerated(0.37) | benign(0) | TCGA-BH-A8G0-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | taxotere | CR |
CHERP | SNV | Missense_Mutation | | c.2193G>C | p.Lys731Asn | p.K731N | Q8IWX8 | protein_coding | tolerated(0.2) | probably_damaging(0.981) | TCGA-E2-A2P6-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Hormone Therapy | anastrozole | SD |
CHERP | SNV | Missense_Mutation | novel | c.91G>C | p.Glu31Gln | p.E31Q | Q8IWX8 | protein_coding | deleterious(0) | probably_damaging(0.992) | TCGA-OL-A5DA-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Unknown | Unknown | SD |
CHERP | insertion | Frame_Shift_Ins | novel | c.925_926insACCTTTTAATTAGATACAGTAAAGA | p.Ala309AspfsTer50 | p.A309Dfs*50 | Q8IWX8 | protein_coding | | | TCGA-AO-A0J5-01 | Breast | breast invasive carcinoma | Female | <65 | III/IV | Other, specify in notesBisphosphonate | zoledronic | PD |
CHERP | deletion | Frame_Shift_Del | novel | c.751delG | p.Ala251ProfsTer404 | p.A251Pfs*404 | Q8IWX8 | protein_coding | | | TCGA-E9-A3HO-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | cyclophosphamide | CR |
CHERP | SNV | Missense_Mutation | rs751451818 | c.2432N>A | p.Arg811His | p.R811H | Q8IWX8 | protein_coding | tolerated(0.2) | benign(0.003) | TCGA-2W-A8YY-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Chemotherapy | cisplatin | CR |
CHERP | SNV | Missense_Mutation | | c.1045N>C | p.Ala349Pro | p.A349P | Q8IWX8 | protein_coding | tolerated(0.19) | benign(0.278) | TCGA-C5-A1BM-01 | Cervix | cervical & endocervical cancer | Female | >=65 | I/II | Unknown | Unknown | SD |
CHERP | SNV | Missense_Mutation | | c.1429N>A | p.Asp477Asn | p.D477N | Q8IWX8 | protein_coding | tolerated_low_confidence(0.05) | benign(0.052) | TCGA-LP-A4AU-01 | Cervix | cervical & endocervical cancer | Female | <65 | III/IV | Chemotherapy | cisplatin | CR |
CHERP | SNV | Missense_Mutation | novel | c.2402N>A | p.Arg801Gln | p.R801Q | Q8IWX8 | protein_coding | tolerated(0.06) | possibly_damaging(0.885) | TCGA-VS-A9V4-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Chemotherapy | cisplatin | PD |
CHERP | insertion | Frame_Shift_Ins | novel | c.62_63insAGAAAGAG | p.Phe22GlufsTer15 | p.F22Efs*15 | Q8IWX8 | protein_coding | | | TCGA-DS-A1OB-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Chemotherapy | carboplatin | PD |